HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress

Patients receiving nine-dose regimen over five months experienced deep and durable reduction in proteinuria, reaching up to ~50% mean reduction in UPCR at end of study at month 24 and over 18 months after last dose Patients across treatment arms exhibited stabilization in eGFR through 24…